MARKET

NBRV

NBRV

Nabriva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.210
+0.030
+2.54%
After Hours: 1.220 +0.01 +0.83% 17:35 09/23 EDT
OPEN
1.180
PREV CLOSE
1.180
HIGH
1.230
LOW
1.180
VOLUME
803.85K
TURNOVER
--
52 WEEK HIGH
6.19
52 WEEK LOW
1.000
MARKET CAP
60.18M
P/E (TTM)
-0.4293
1D
5D
1M
3M
1Y
5Y
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 09/16 13:03
Nabriva Therapeutics Plc (NBRV) CEO Theodore R Schroeder Bought $56,500 of Shares
GuruFocus News · 09/16 12:15
Nabriva Therapeutics, Vizient Inks Xenleta Distribution Pact
Benzinga · 09/09 14:02
BRIEF-Nabriva And Vizient Enter Into Agreement To Make Xenleta Available To Vizient's Pharmacy Network Program
reuters.com · 09/09 11:27
Nabriva and Vizient Enter Into Agreement To Make XENLETA Available To Vizient's Pharmacy Network Program
Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has entered into an
Benzinga · 09/09 11:11
Nabriva and Vizient Enter into Agreement to Make XENLETA(R) (lefamulin) Available to Vizient's Pharmacy Network Program
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has entered into an agreement with Vizient to offer XEN...
GlobeNewswire · 09/09 11:01
IGC, NCMI and BBIG among pre market gainers
Kadmon Holdings (NASDAQ:KDMN) +74% Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B Gain Therapeutics (NASDAQ:GANX) +27% on positive GT-02287and GT-02329 data in Parkinson’s disease Alset EHome International (NASDAQ:AEI) +15% inv...
Seekingalpha · 09/08 12:21
BRIEF-Lefamulin Receives Approval In Taiwan For Treatment Of Community-Acquired Pneumonia
reuters.com · 09/08 11:18
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBRV. Analyze the recent business situations of Nabriva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBRV stock price target is 2.675 with a high estimate of 4.000 and a low estimate of 1.350.
EPS
Institutional Holdings
Institutions: 81
Institutional Holdings: 13.92M
% Owned: 28.00%
Shares Outstanding: 49.74M
TypeInstitutionsShares
Increased
6
952.63K
New
4
61.35K
Decreased
7
320.48K
Sold Out
6
223.54K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director/Supervisory Board
Daniel Burgess
President/Chief Operating Officer/Director
Steven Gelone
Chief Executive Officer/Director
Theodore Schroeder
Chief Financial Officer
Daniel Dolan
General Counsel/Secretary
Robert Crotty
Director
Colin Broom
Independent Director/Supervisory Board
Carrie Bourdow
Independent Director/Supervisory Board
Mark Corrigan
Independent Director/Supervisory Board
Lisa Dalton
Independent Director/Supervisory Board
Charles Rowland
Independent Director/Supervisory Board
Stephen Webster
No Data
About NBRV
Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Webull offers kinds of Nabriva Therapeutics PLC - ADR stock information, including NASDAQ:NBRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBRV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBRV stock methods without spending real money on the virtual paper trading platform.